Infections after bone reconstructive surgery are a real therapeutic and economic issue for the modern health care system. As the pathogen (most often Staphylococcus aureus) is able to develop a biofilm inside the bone, local delivery of antibiotics is of interest since high drug concentrations would be delivered directly at the target place. In this context, this study evaluated a porous hydroxyapatite implant as biocompatible bone substitute and vancomycin-delivery system to prevent post-operative infections. A simple method of impregnation with optimised conditions insured a high antibiotic loading (up to 2.3 AE 0.3 mg/m 2 ), with a complete in vitro release obtained within 1-5 days. Additionally, the bacteriostatic and bactericidal effects of vancomycin were retained after loading on hydroxyapatite, as demonstrated after challenge with a Staphylococcus aureus strain. Regarding the biocompatibility, a wound healing assay of preosteoblastic MC3T3-E1 cells exposed to various concentrations of vancomycin revealed a dose-dependent reduction in cell migration for antibiotic concentrations higher than 1 mg/mL. Meanwhile, cells were able to proliferate normally on vancomycin-loaded scaffolds, although cell initial adhesion was seriously impaired for scaffolds loaded with 2.3 mg/m 2 . Loaded scaffolds could be stored up to three months at room temperature without any degradation of the antibiotic. Together, these results demonstrate the efficacy of these hydroxyapatite bone substitutes for local delivery of vancomycin in the context of bone infection.
Introduction
The reconstruction of bone defects resulting from osteoporosis, trauma or tumour resection provides a unique challenge for orthopedic surgeons. Indeed, the ideal filling material should not only exhibit high biocompatibility, osteointegration and biodegradability, but also possess anti-infectious properties. As a matter of fact, implant-associated infection is a common postoperative complication, with a risk up to 23% for severe open fractures. 1 In addition to constituting a significant burden on healthcare systems, postoperative infections have severe consequences for the patients in terms of pain, morbidity and mortality. Staphylococci species (and especially Staphylococcus aureus) are the causal pathogens in almost half of the cases, 2 although Gram-negative bacteria or even fungi might be involved. Within the first hours after contamination, bacteria initiate formation of biofilm which becomes mature within 24 h. 3 As a result, adherent bacteria clusters are embedded in a thick extracellular matrix and this structure protects them both from the host immune system and antibiotic treatments. 4, 5 Eradication of implant-associated infection is extremely difficult to achieve, since bone/plasma ratios of antibiotics concentration after parenteral administration is often poor and drug penetration into the infectious site is additionally hindered by the biofilm. 5 Moreover, bacteria are increasingly resistant to antibiotics, as evidenced for example by the high frequency of methicillin-resistant Staphylococcus aureus (MRSA) (56. .4% according to Rosenthal et al. 6 ). In view of the above, the most direct and effective approach to solve implant-associated infection problem is to integrate a controlled antibiotic delivery system into the bone substitute, to release antibiotic directly in the local sites of bone defects, and, if possible, in a prophylactic rather than a therapeutic purpose.
In the context of scarce discovery of new antibiotics and rapid emergence of multidrug-resistant pathogens, bacterial infections are increasingly difficult to treat, especially when bacterial biofilms are involved as in the case of bone infections. The choice of the antibiotic should be well considered, in order to efficiently eradicate or prevent infection, and without promoting the development of drug resistance and impairing the natural bone healing process. Accordingly, vancomycin was an obvious choice for the study, as it is a broad-spectrum antibiotic from the glycopeptide family, active against the Gram-positive bacteria, with a low frequency of resistance up to now. Moreover, several studies have demonstrated in vitro that vancomycin is far less toxic against mammalian cells than other antibiotics. 7 Hydroxyapatite (HA, Ca 10 (PO 4 ) 6 (OH) 2 ) is the inorganic component of human's teeth and bones, thus synthetic HA has been widely used as scaffolds for bone defects filling due to its great biocompatibility, osteointegration and osteoconductivity. 8, 9 Also, because of the known ability of HA to adsorb pharmacological agents at its surface, a large number of HA-based materials have been developed as drug delivery systems, for anticancer agents, enzymes, growth hormones, antibiotics, anti-inflammatory drugs, etc. 10, 11 One of the key features of HA bone substitutes is their porosity, which will influence both their drugdelivery properties and their colonisation by cells for bone reconstruction (osteoconduction). On the one hand, interconnected pores with large diameters (300-600 mm) are necessary for cell penetration and proliferation in the bulk of the scaffold. On the other hand, the loading and release of drug substance can be controlled using pores with smaller diameter, in the micrometer range, that can be produced in the ceramic walls of the macroporous structure. These pores can be used as drug reservoir and the drug release kinetic will depend on their size. 12 As these two kinds of pores have different roles that can be dissociated, the aim of the study was to investigate the ability of HA microporous scaffolds to adsorb and control the release of vancomycin hydrochloride. As a result, scaffold composition and sintering parameters were chosen to obtain a given micro-porosity (40-200 nm) and no larger pores. As the finality is to prevent infection and biofilm formation after implantation, scaffolds were challenged with a Staphylococcus aureus strain. Viability with murine pre-osteoblastic cells and cell proliferation were also evaluated. This study provides a better understanding of the hydroxyapatite/vancomycin interactions and of the influence on pre-osteoblastic cells of, on the one hand, vancomycin itself, and on the other hand, of vancomycin-loaded scaffolds. This will help to rationalise the development of future tri-dimensional HA vancomycin-delivery systems.
Material and methods

Hydroxyapatite scaffolds elaboration
Pure hydroxyapatite (HA: Ca 10 (PO 4 ) 6 (OH) 2 ) powder was synthesised in the laboratory by an aqueous precipitation method as described elsewhere. 13 Before ceramic scaffold elaboration, raw powder was calcined in a Super Kanthal furnace (Sandvik, Hallstahammar, Sweden) at 650 C for 30 min with a heating rate of 20 C/min. Then, HA porous pellets were produced by uniaxial pressing at 125 MPa followed by natural sintering (Super Kanthal furnace, rate: 20 C/min, stage: 1000 C/30 min). The obtained scaffolds had approximately the following characteristics: 300 mg weight, 9 mm diameter and 2.2 mm thickness.
Physicochemical characterisation
The crystalline phases were determined by X-ray diffraction (Siemens D5000 y/2y diffractometer, Siemens Analytical X-Ray Instruments, Madison, USA) using CuKa radiation, a step size of 0.020 and a counting time of 4 s. The identification of crystalline phases was achieved with EVA software Õ by comparing the diffraction patterns with International Centre for diffraction Data-Powder Diffraction Files (ICDD-PDF). The phase purity of HA was verified on calcined powder (1000 C/15 h) according to the standard specifications of ISO 13779-3:2008. 14 Fourier transform infra-red (FTIR) spectra were registered in transmission (range: 4000-400 cm À1 , resolution: 2 cm À1 ) using a Perkin Elmer Spectrum One FTIR spectrometer (Waltham, USA). Porosity measurements were carried out using a mercury intrusion porosimeter (Autopore IV 9500; Micromeritics Instruments Inc., Norcross, USA) equipped with a 5 cm 3 powder penetrometer. Cumulative and incremental mercury intrusion volumes were recorded. Specific surface area (SSA; m 2 /g) was measured by nitrogen adsorption according to the BET method (eight points) using an ASAP 2020 V4 apparatus (Micromeritics Instruments Inc., Norcross, USA) after degassing under vacuum at 250 C. Morphological investigation of scaffolds sputtercoated with platinum was performed by field-emission gun scanning electron microscopy (FEG-SEM) using a JEOL JSM-7400 F microscope (Tokyo, Japan). To evaluate the change of HA surface as a function of the vancomycin concentration of the loading solution, zeta potential measurements were carried out on HA powder suspensions with a Zetasizer Nano ZS apparatus (Malvern Instruments, Worcestershire, UK). To obtain a similar surface as sintered pellets, powder was first heated in the same conditions as sintered scaffolds at 1000 C for 30 min, and then 0.1 g of HA was suspended in 4 mL of water or vancomycin solution at 10, 20, 30, 40 or 50 mg/mL (pH 7.00 AE 0.05). After 2 h of contact under magnetic stirring, supernatants were diluted in water 1:500 before analysis. Three measurements were taken at 25 C for each sample and the Smoluchowski model was used for the zeta potential calculation.
Vancomycin loading
Solutions of vancomycin hydrochloride 50 mg/mL were obtained by dissolving the powder (Vancomycine Sandoz Õ 1 g for parenteral administration, Holzkirchen, Germany) in distilled water immediately before use. For all solutions, the pH was adjusted to 7.00 AE 0.05 with NaOH 1 M (Sigma-Aldrich, Saint-Louis, USA). The adsorption experiments were performed at room temperature (and protected from light) by applying 1 min of vacuum before soaking each scaffold in 10 mL of vancomycin solution during a given contact time and under agitation on a roller shaker. Afterwards, scaffolds were dried overnight at 37 C and then stored at room temperature protected from light.
On the one hand, adsorption kinetics was evaluated by soaking the scaffold in a 50 mg/mL vancomycin solution for a period ranging from 15 min to 2 h. On the other hand, adsorption isotherm was obtained by soaking the scaffold for 2 h in solutions with vancomycin concentrations from 10 to 50 mg/mL. The adsorbed amount of drug was quantified by dissolving the scaffolds in HCl 2.4 M (prepared from HCl ! 37%, Sigma-Aldrich, Saint-Louis, USA) before measuring the vancomycin concentration by UV spectrophotometry (Lambda 20, Elmer Perkin) at ¼ 280 nm. Drug loading was deduced from a calibration curve of vancomycin in HCl (range 0.01-0.3 mg/mL, Abs ¼ 4.2625 Â C vancomycin (mg/mL) À 0.0014, R 2 ¼ 0.9998) and normalised by the SSA of the scaffold. Control scaffolds (V0) were obtained by applying the same adsorption protocol, but with demineralised water with pH adjusted to 7.00 AE 0.05 instead of vancomycin solution.
Scaffolds were named V10, V20 or V50 according to the concentration of the vancomycin solution (10, 20 or 50 mg/mL, respectively) used for impregnation.
Vancomycin in vitro release studies
Antibiotic release studies were carried out by immersing each implant in 2 mL of phosphate buffer saline (1X PBS, Gibco, Thermo Fisher Scientific, Waltham, USA) in a 24-well plate, at 37 C with orbital shaking (Heidolph Unimax 1010, Schwabach, Germany) at 30 r/min. The medium was removed and replaced by 2 mL of fresh preheated medium at given time intervals. For each sample, the vancomycin concentration was determined by UV-spectroscopy (Lambda 20, Perkin Elmer, Waltham, USA) at ¼280 nm, using a calibration curve of vancomycin in PBS (range 0.01-0.3 mg/ mL, Abs ¼ 4.0952 Â C vancomycin (mg/mL) þ 0.0064, R 2 ¼ 0.9985). At each time point, the release medium obtained from V0 implants was used to calibrate the baseline.
Stability of loaded vancomycin
Vancomycin-loaded scaffolds were stored at room temperature protected from light. To assess the absence of antibiotic degradation in these conditions, a HPLC method modified from Backes et al. was used. 15 Briefly, scaffolds were dissolved in HCl 2.4 M, and 20 mL of the diluted solution was injected into the HPLC system composed of a Varian 9010 pump (Varian Medical Systems, Palo Alto, USA), a Waters Symetry C18 column (5 mm particle size, 250 Â 4.6 mm, Milford, USA) and a Varian 9050 detector set at ¼ 210 nm. Flow rate was 1.5 mL/min and a gradient between mobile phases A and B was used (phosphate buffer 0.5 M pH 6/acetonitrile/methanol, 91/5/4% v/v and 84/8/8% v/v, respectively): isocratic at 0% B for 2 min, linear gradient to 50% B over 1 min, isocratic at 50% B for 1 min, linear gradient to 80% B over 1 min, isocratic at 80% B for 8 min. Solvents were of HPLC grade and obtained from Sigma-Aldrich (Saint-Louis, USA). A 5-min reconditioning time was allowed between each analysis. Chromatograms were acquired with the Azur 5.0.10.0 software (Datalys, Le Touvet, France). A fresh solution of vancomycin was used as reference. The same solution was subjected to a forced degradation (48 h, 60 C) to show the peaks of the two degradation products of vancomycin, CDP-I m (relative retention time rrt ¼ 0.5) and CDP-I M (rrt ¼ 0.8). 15 
Bacterial culture and antibacterial effect assays
For bacteria and cell assays, scaffolds were sterilised by heat (stove at 200 C, 2 h) before being loaded with sterile vancomycin solutions on sterile conditions under laminar flow.
Staphylococcus aureus strain ATCC 6538 P (Fisher Scientific, Illkirch, France) was propagated overnight before experiments. Bacteria were then suspended in sterile solutions and bacterial concentrations were assessed by optical density at 620 nm according to McFarland standards.
First, a solid diffusion assay was used to verify the biological activity of the released vancomyin. A Staphylococcus aureus suspension (10 7 cells/mL in water) was inoculated on Difco antibiotic medium 3 agar plates (Fisher Scientific) and scaffolds were deposited on the plate surface. After incubation for 16-24 h at 37 C, diameters of inhibition zones (including the diameter of the scaffold) were determined by using a Haloes Caloper (IUL Instruments, Delta Labo, Avignon, France).
Second, scaffolds were incubated in 4 mL of a Staphylococcus aureus suspension (5 Â 10 7 cells/mL of buffer, pH 7.00 16 at 37 C under agitation. Then 100 mL of media were collected after 6 h, 24 h and 48 h and serially diluted 10-fold. Also 1 mL of each diluted suspension was used for plate inoculation in duplicate. After 24 h-incubation at 37 C, colony-forming units were quantified and compared to the control, i.e. scaffolds without vancomycin. Experiments were performed twice. After 48 h, scaffolds were gently washed twice with PBS to remove non-adherent bacteria and then fixed in 2.5% glutaraldehyde for 2 h at 4 C, washed twice with PBS and finally dehydrated through a series of acetone solutions (30-100%). The samples were subsequently freeze-dried, sputter coated with platinum, and observed by scanning electron microscopy (SEM) (FEG-SEM, JEOL JSM-7400 F microscope, Tokyo, Japan).
Cell culture conditions
Murine calvaria pre-osteoblast MC3T3-E1 cells (DSMZ, Braunschweig, Germany: ACC 210) were cultured in alpha-modified Eagle's medium (a-MEM; Gibco, Thermo Fisher Scientific, Waltham, USA) containing 2 mM L-glutamine (Gibco) and supplemented with 10% foetal calf serum (Biochrom, Cambridge, UK), 50 UI/ml penicillin and 50 mg/mL streptomycin (Gibco) in an incubator heated at 37 C under 5% CO 2 humidified atmosphere. For routine cultivation, the cells were seeded in T75 flasks (Sarstedt, Nu¨rnbrecht, Germany), and the medium was replaced every 2-3 days and cells were subcultured when cell confluence reached 70-80% of the culture area.
Impact of vancomycin solutions on pre-osteoblastic cells viability and migration
The toxicity of vancomycin on MC3T3-E1 cells was evaluated by MTT-assay. MC3T3-E1 cells were seeded at a density of 8 Â 10 3 cells/well in a 96-well plate and left for 4 h to adhere. Then 100 mL of the medium was exchanged for vancomycin-containing medium, at concentrations ranging from 0.25 to 3.75 mg/mL and incubated 24, 48 or 72 h at 37 C. The experiment was conducted twice at each incubation time, with three replicates for each condition. Medium was withdrawn and replaced by 50 mL of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2 H-tetrazolium bromide, 2 mg/mL in culture medium, Sigma-Aldrich, Saint-Louis, USA) and incubated for 1 h at 37 C. Cells were then lysed with 100 mL of DMSO (Gibco Thermo Fisher Scientific) at room temperature for 15 min under agitation. Finally, absorbance was read at 595 nm with a plate reader (Multiskan FC, Thermo Fisher Scientific). Incubation with culture medium or with medium supplemented with H 2 O 2 from Sigma-Aldrich (5% v/v, 4 h of incubation) was used as negative and positive control of cell toxicity, respectively.
To estimate the potential impact of vancomycin on pre-osteoblast migration, a wound-healing assay was used. Cells were seeded at a density of 2.4 Â 10 5 cells/ well in a 6-well plate, in 2 mL of culture medium. When confluence was reached, a scratch was made in each cellular layer with a P1000 tip, simulating a wound. Culture medium was changed for vancomycin-containing medium (0.25-3.75 mg/mL) or culture medium (complete a-MEM medium: control). Pictures were taken immediately after wound, at 12 h and at 24 h with a Leica DMI 8 microscope equipped with a camera (Leica Microsystems, Wetzlar, Germany). For each condition, four determined scratch areas (two different scratches, two areas per scratch) were observed. Microphotographs were analysed with ImageJ software (NIH, http://rsb.info.nih.gov/ij/) to compare the evolution of wound areas.
Biocompatibility of vancomycin-loaded scaffolds
In a 24-well plate, an amount of 5 Â 10 4 cells in 1 mL of complete a-MEM was seeded drop by drop onto each scaffold (or glass coverslip for control). After 3 h of incubation, the medium was renewed to remove nonadherent cells. After 24, 48 or 72 h of incubation, cell proliferation was highlighted by using the Click-iT Õ EdU Alexa Fluor Õ 488 Imaging Kit (Molecular Probes, Thermo Fischer Scientific) according to the manufacturer's instructions. Briefly, half of culture supernatant was discarded from 24-well plate cultured cells and replaced by 20 mM EdU solution in culture medium to obtain a final EdU concentration of 10 mM. EdU incorporation was allowed for 4 hours at 37 C. After this time, cells were fixed in absolute icecold methanol (Sigma-Aldrich, Saint-Louis, USA) for 7 min at room temperature, rinsed twice with PBS. Cells were then rinsed twice with PBS-BSA 3% solution, permeabilised for 20 min at room temperature in PBS-Triton-X100 0.5% and rinsed twice again in PBS-BSA 3% (BSA and Triton-X100 from Thermo Fisher Scientific). Scaffolds with cells were immersed for 30 min in Click-it reaction buffer freshly prepared according to the manufacturer's instructions. Cells were then rinsed twice in PBS and nuclei were stained with HOESCHT 33342 (Thermo Fischer Scientific) 20 mM in PBS for 7 min at room temperature. Scaffolds were finally observed under AxioImager M2 microscope (Carl Zeiss, Oberkochen, Germany) and pictures were taken and processed using the AxioVision 4 software (Carl Zeiss). For each experiment, the analysis was performed on at least 10 fields to cover all the surface of the sample. Microphotographs were analysed with ImageJ software. The proliferation rate was determined by establishing the percentage of EDU positive cells on total cells (nuclei stained by HOESCHT 33342).
Statistical analysis
Unless otherwise specified, experiments were performed in triplicate, and the results were expressed as means AE SD. Significant statistical differences between means were evaluated by using the ANOVA test with Bonferroni post-tests, with p < 0.05 considered as significant.
Results
Hydroxyapatite scaffolds elaboration
The FTIR spectrum and XRD pattern confirmed that the synthesised product was pure hydroxyapatite, with a Ca/P molar ratio of 1.667 as no trace of other phase was detected. The X-ray diffraction patterns of HA samples exhibit a unique crystalline hydroxyapatite phase indexed by the pattern ICDD-PDF 09-0432 in both calcined powder and sintered pellets. No secondary crystalline phase (i.e. b-tricalcium phosphate or calcium oxide) is detected (data not shown). The FTIR spectrum presents only the vibration modes of phosphate and hydroxide groups in apatite structure: antisymmetric stretching mode n 3 PO 4 at 1040 cm À1 and 1090 cm À1 , symmetric stretching n 1 PO 4 at 962 cm À1 , antisymmetric n 4 PO 4 and symmetric n 2 PO 4 bending modes at 571-603 cm À1 and 475 cm À1 and stretching (n S ) and libration (n L ) modes of the hydroxide at 3573 cm À1 and 630 cm À1 , respectively (data not shown). Calcined HA powder (1000 C/30 min) used for zeta potential measurements had a SSA of 9 m 2 /g. Sintered pellets had a SSA of 4 m 2 /g and exhibited typical porous HA surfaces (Figure 1(a) ). Their porosity was 25%, with nanometer-sized pores (D v,50 ¼ 83 nm) and distribution almost monomodal in the range of 40-200 nm with the main peak centred at 86 nm and the presence of a pore population in the range of 100-200 nm (Figure 1(b) , black line).
Vancomycin loading and in vitro release studies
The drug adsorption was studied by varying two parameters, the immersion time and the vancomycin solution concentration.
The drug loading is a nonlinear function of immersion time (not shown), with a fast uptake during the first 15 min (with 1.4 AE 0.3 mg/m 2 loaded after this time) then a slowdown (with a final load of 2.3 AE 0.3 mg/m 2 after 2 h). Longer immersion times were not allowed, due to the known potential degradation of vancomycin in solution, which intensity depends on time, temperature and pH. 15 Additionally, solutions incubated for longer times tend to become milky, probably due to the precipitation of vancomycin (close to its solubility limit in these conditions), as the degradation of HA has been ruled out by the controls (no turbidity was observed in the solution when scaffolds were incubated in pure water at pH 7.00, whatever the incubation time). Anyway, HA is very slightly soluble in water, with a solubility constant Ks of about 10 À60 (for the chemical formula Ca 5 (PO 4 ) 6 (OH)). 17 Vancomycin loading as a function of immersion solution concentration (immersion time 2 h, Figure 2(a) ) is typical of a multilayer system, with a monolayer coating obtained for concentrations between 20 and 40 mg/mL. The SEM photographs (Figure 2(d) ) confirmed a modification of scaffolds surface. V10 scaffolds were partly covered by vancomycin platelets and HA was still visible in some regions. V20 scaffolds showed a homogenous surface covered with small aggregates while V50 scaffolds surface was totally covered by overlapping vancomycin platelets. A shift in zeta potential (Figure 2(b) ) was also observed for HA immersed in 10 mg/mL or 20 mg/mL vancomycin solutions, confirming a modification of the surface.
A small fraction of the drug is able to penetrate the pores of the scaffolds, as shown in Figure 1(b) for a scaffold loaded with 50 mg/mL of vancomycin (V50). Porosity was reduced (from 25 to 21%) and the pore distribution becomes almost monomodal, with the disappearance of the (100-200 nm) pores population while the median pore diameter D v,50 was slightly reduced (from 83 to 72 nm).
The cumulative released vancomycin vs time from scaffolds loaded in different conditions is presented in Figure 2 (c). V20 scaffolds exhibit the fastest and sharpest release (81.0 AE 2.8% released after 1 h), completed within 24 h. V10 scaffolds release was also completed during the first day, but with a smoother release profile (25.5 AE 1.6% released at 1 h). Finally, V50 scaffolds display a high initial release during the first 8 h (61.7 AE 0.4 %) followed by a sustained release up to five days. At the end of experiments, scaffolds were dissolved in HCl and absorbance of solutions was recorded as previously described. No trace amount of drug was found, demonstrating a complete release in 24 h for V10 and V20 and 5 days for V50.
Stability of loaded vancomycin scaffolds during storage
The chromatograms revealed that there was no significant difference between a fresh solution of vancomycin or a solution obtained from a V50 scaffold stored up to three months (Figure 3) . Notably, the two CDP-I degradation products of vancomycin (highlighted at 5 and 8 min) were not found and no peak was observed at higher retention times in chromatograms recorded during 45 min. This is an important point as the degradation by-products (CDP-I) do not have antibiotic activity. 15 
Antibacterial effect
The vancomycin-loaded scaffolds retain the biological activity of the antibiotic, as shown first in the bacteriostatic drug diffusion assay (Figure 4(a) and (b)) and confirmed in the bactericidal assay (Figure 4(c) ).
In the drug diffusion assay, a substantial and dosedependent inhibition zone is observed around each vancomycin-loaded scaffold (Figure 4(b) ), while no inhibition is detected around the water-loaded control scaffolds (Figure 4(a) ). Regarding the bactericidal assay (Figure 4(c) ), a slight decrease of the bacterial concentration is observed in the control conditions (V0) during the 48 h of assay, which can be explained by the bacterial adhesion to the scaffold, and/or by the incubation buffer solution used. By contrast, a drastic reduction of bacterial concentration is observed for vancomycin-loaded scaffolds, with a complete eradication of viable colony-forming units in suspension from 6 h for the scaffold with the highest antibiotic load (V50), and from one day of incubation for V10 and V20. Loading of HA scaffolds with vancomycin resulted not only in killing of planktonic bacteria, but also in reducing the quantity of bacteria attached to the HA surface after 48 h of incubation, in a dose-dependent manner (Figure 4(d) ). The few bacteria on V50 scaffolds displayed a different morphology, with a shift from spherical shapes to irregularly condensed masses. This has been previously observed in other studies 18 and is probably linked with the mechanism of action of vancomycin, which inhibits a critical step in bacterial cell wall peptidoglycan synthesis. 19 Interestingly, there was no visible vancomycin on the surface of the scaffolds after 48 h of incubation, which was consistent with the in vitro release study (Figure 2(c) ). 
Vancomycin effect on pre-osteoblastic cells
First, vancomycin exposition led to a significant and transitory dose-dependent increase in MTT metabolism by MC3T3-E1 cells (data not shown). After 48 h, no more differences could be observed between vancomycin concentrations below 1 mg/mL and the control. After 72 h, the signal returned to normal for all vancomycin concentrations (0.25-3.75 mg/mL). Even at high concentrations (3.75 mg/mL), vancomycin was not toxic for MC3T3-E1 cells after three days of incubation. However, a transitory and dose-dependent increase in mitochondrial succinate dehydrogenase activity (reflecting an increase in cell metabolic activity) was highlighted after treatment, suggesting that cells suffered a stress. Second, the antibiotic impaired cell migration, as shown in the wound healing assay ( Figure 5 ). Wound healing at 24 h was reduced by 15-20% for vancomycin concentrations between 1 and 2.5 mg/mL and by quite 50% for a 3.75 mg/mL concentration.
Finally, vancomycin significantly affected cell density after 24 h, 48 h and 72 h for the highest load as shown by the highly reduced cell density on V50 scaffolds at 24 h (Figure 6(a) ). However, except for V50, cell population growth was comparable on all HA substrates. Regarding the proliferation rate ( Figure 6(b) ), whatever the incubation time and the substrate, all cells were able to integrate the fluorescent nucleotide EdU in their genetic material during its duplication ( Figure 6(b) ). Consequently, since no obvious toxicity of vancomycin was observed with MTT assay (data not shown) and the proliferation rate was not impacted, the antibiotic likely impacted cell adhesion.
Discussion
Standard therapies for bone infection (surgical removal of necrotic tissues followed by long-term parenteral and oral antibiotherapy at high doses) are often insufficient to obtain bacterial eradication. Because of the poor penetration of antibiotics into the bone tissue and especially into infected one, systemic treatment is generally unable to ensure efficient local drug concentration without systemic toxicity (e.g. nephro-and oto-toxicities). Consequences for the patient, the health care system and the community are thereafter very heavy. According to this, the implementation of preventive measures against infection during bone surgery is probably a less-expensive and more effective strategy. In this sense, local administration of antibiotic directly into the surgical wound is a common practice and is progressively recognised as an efficient way to significantly reduce infection rates, for example after spinal surgery. 20 Although effective, this method does not allow a controlled and progressive drug release and therefore exposes the surrounding tissues to a potentially toxic high drug concentration. In contrast, antibiotic-loaded cements, scaffolds or bone allografts 21-23 allow a sustained release of the antibiotic and show both antibacterial and bone substitute properties.
However, the integration or linkage of the drug to the delivery system should not result in drug degradation and loss of antibiotic properties. In this study, vancomycin loading on porous HA was obtained with a very simple and neither costly nor time-consuming process. Depending on the concentration of the immersion solution, various loadings (0.7 AE 0.1 to 2.3 AE 0.3 mg/m 2 ) and different release profiles could be obtained (Figure 2) . Stability of the antibiotic after loading and storage was demonstrated upon three months at room temperature (Figure 3) .
In order to study the influence of antibiotic loading method parameters on vancomycin load and release, composition of scaffolds and sintering parameters were chosen to obtain porous bone substitutes with a narrow distribution of pores in the range of 50-200 nm (Figure 1 ). The absence of macrometer-size pores was necessary to study specifically the drug/scaffold interactions and determine the best loading parameters. Concerning the in vitro studies, only interactions with the surface of the scaffolds were studied for bacteria and pre-osteoblastic cells. Nevertheless, development of a macro-porosity will be a prerequisite in further in vivo studies to allow a suitable osseous cell colonisation of the HA and adequate bone reconstruction.
Intuitively, the scaffold with the highest loading and the most sustained release (i.e. V50) should be the most promising for preventing bone infection. The first key point is to reach a vancomycin tissue level above the minimum eradication concentration. This value was established in vitro to be in the range of 8-16 mg/mL for planktonic Staphylococcus aureus bacteria and above 1024 mg/mL when the same bacteria are embedded in biofilms. 4 In the in vitro release assay (Figure 2 ), high vancomycin concentrations have been obtained in the release medium (2 mL) for each of the three tested loading and for every harvest time. These concentrations were obtained with a regular complete medium renewal and were around 75 mg/mL, 375 mg/mL and 225 mg/mL for V10, V20 and V50, respectively, at the first sampling points. These values are 5-23 times higher than the minimum eradication concentration for planktonic bacteria indicated above. In deviceassociated infections, the initial 6 h following implantation are recognised as the critical phase corresponding to bacterial adhesion. 24 Mean concentrations of vancomycin in release medium sampled at 6 h were 15 mg/mL for V10, 15 mg/mL for V20 and 25 mg/mL for V50, therefore still above the indicated target. Of course, these concentrations could be used as a tool to compare in vitro the performance of several formulations, but are not reliable predictors of the in vivo concentrations obtained after scaffold implantation. Although the experimental set-up for in vitro release (small volume of 2 mL, agitation, temperature) was designed to approach the bone environment, this latter is really complex and changing (fluids composition, quantity and flow, pH, temperature, oxygen pressure, mechanical stimuli, and so on).
The second key point is the release profile itself: with or without burst, with or without release tail and for which total duration? Although a high level vancomycin release (as it is the case for V50, see Figures 2 and 4) is probably better for bacteria killing, it could expose, in turn, to a greater risk of antibiotic resistance development when extended for several days (as it is the case for V50, see Figure 2 ). As the benefit-risk ratio of local prophylactic vancomycin delivery should be carefully evaluated, due to the possible development of drug resistance, V10 and V20 scaffolds may appear as attractive alternatives to V50, with a drug release completed within 12-24 h whilst efficiently reducing Staphylococcus aureus adhesion to the HA porous scaffold. In the future, an additional drug such as quorum sensing inhibitors 25 could be co-loaded in these systems, in order to improve the antibacterial effect and to enlarge the applications to established bone infections with already existing biofilms. Moreover, the interest of these vancomycin-delivery systems is linked not only to their ability to delay bacterial colonisation, but also to their role as bone substitute facilitating bone repair. High load and massive antibiotic release could be very efficient on bacteria whilst negatively impacting cells and bone regeneration processes.
In this sense, the impact of vancomycin on preosteoblastic cells was studied in vitro. Results indicate that vancomycin impairs MC3T3-E1 adhesion but not their growth on HA, especially in the case of V50 scaffolds ( Figure 6 ). This can be explained by the results from MTT assays (data not shown) and Figure 5 , indicating that at concentrations above 1 mg/mL, vancomycin induces a dose-dependent stress for the cells, with stimulation of their mitochondrial activity and diminution of their motility. According to their respective loadings, theoretical maximal concentrations of vancomycin reached in the medium of scaffolds seeded with MC3T3-E1 cells could be 0.6 mg/mL, 1.5 mg/mL and 3 mg/mL for V10, V20 and V50, respectively. The threshold of 1 mg/mL could be therefore easily exceeded in vitro by V50 releasing only 30% of their load. These in vitro results are consistent with those of Pon-On et al., 26 who observed that vancomycin delays pre-osteoblast adhesion on loaded CaPcollagen structures in the earlier 1-5 days of culture but was not toxic for the cells. However, extrapolation of these considerations to the in vivo situation has to be modulated again, as other studies have shown that vancomycin does not interfere with normal in vivo bone regeneration. 27, 28 
Conclusions
It was possible to obtain several vancomycin loading and release profiles from a porous hydroxyapatite bone substitute by varying the concentration of the immersion solution. Loaded scaffolds could be stored at room temperature for at least three months without drug degradation. All tested scaffolds showed good bactericidal properties against Staphylococcus aureus, but a significant reduction of pre-osteoblastic cells adhesion was highlighted for the scaffold with the highest vancomycin loading (V50).
In conclusion, V10 and V20 scaffolds have demonstrated in vitro their ability to inhibit Staphylococcus aureus adhesion on HA together with their good compatibility with pre-osteoblasts. In vivo studies should be conducted to confirm their applicative potential as bone substitute preventing bone infection in pre-clinical models with multi-bacterial inoculum.
